ZA201501958B - Tert-butyl n-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2h)-yl]-3,5-difluorophenyl}ethyl]-l-alaninate or a salt, hydrate or solvate thereof - Google Patents

Tert-butyl n-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2h)-yl]-3,5-difluorophenyl}ethyl]-l-alaninate or a salt, hydrate or solvate thereof

Info

Publication number: ZA201501958B
Authority: ZA; South Africa
Prior art keywords: oxopyridin; difluorobenzoyl; alaninate; difluorophenyl; solvate
Prior art date: 2012-10-17

Application number

ZA2015/01958A

Other languages

English (en)

Inventor

Stephen John Davies

David Festus Charles Moffat

Stephane Pintat

Original Assignee

Chroma Therapeutics Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-10-17

Filing date

2015-03-20

Publication date

2016-01-27

2012-10-17 Priority claimed from GBGB1218640.9A external-priority patent/GB201218640D0/en

2013-04-16 Priority claimed from GB201306881A external-priority patent/GB201306881D0/en

2015-03-20 Application filed by Chroma Therapeutics Ltd filed Critical Chroma Therapeutics Ltd

2016-01-27 Publication of ZA201501958B publication Critical patent/ZA201501958B/en

Links

150000003839 salts Chemical class 0.000 title 1
239000012453 solvate Substances 0.000 title 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)

ZA2015/01958A 2012-10-17 2015-03-20 Tert-butyl n-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2h)-yl]-3,5-difluorophenyl}ethyl]-l-alaninate or a salt, hydrate or solvate thereof ZA201501958B (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB1218640.9A GB201218640D0 (en)	2012-10-17	2012-10-17	Chemical compounds
GB201306881A GB201306881D0 (en)	2013-04-16	2013-04-16	Chemical compounds
PCT/GB2013/052689 WO2014060742A1 (en)	2012-10-17	2013-10-15	Tert-butyl n-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2h)-yl]-3,5- difluorophenyl}ethyl]-l-alaninate or a salt, hydrate or solvate thereof

Publications (1)

Publication Number	Publication Date
ZA201501958B true ZA201501958B (en)	2016-01-27

Family

ID=49488610

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA2015/01958A ZA201501958B (en)	2012-10-17	2015-03-20	Tert-butyl n-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2h)-yl]-3,5-difluorophenyl}ethyl]-l-alaninate or a salt, hydrate or solvate thereof

Country Status (27)

Country	Link
US (3)	US9388136B2 (sr)
EP (2)	EP3222616B1 (sr)
JP (2)	JP6260975B2 (sr)
KR (1)	KR102164536B1 (sr)
CN (2)	CN106496106B (sr)
AU (1)	AU2013333636B2 (sr)
BR (1)	BR112015008167B1 (sr)
CA (1)	CA2888928C (sr)
CY (2)	CY1119080T1 (sr)
DK (2)	DK2909175T3 (sr)
ES (2)	ES2743768T3 (sr)
HR (2)	HRP20171320T1 (sr)
HU (2)	HUE046132T2 (sr)
IL (2)	IL237863B (sr)
IN (1)	IN2015DN02721A (sr)
LT (1)	LT3222616T (sr)
MX (1)	MX364782B (sr)
NZ (1)	NZ706717A (sr)
PL (2)	PL3222616T3 (sr)
PT (2)	PT2909175T (sr)
RS (2)	RS59458B1 (sr)
RU (1)	RU2676329C2 (sr)
SG (2)	SG10201708166SA (sr)
SI (2)	SI2909175T1 (sr)
SM (2)	SMT201700399T1 (sr)
WO (1)	WO2014060742A1 (sr)
ZA (1)	ZA201501958B (sr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL3222616T3 (pl) *	2012-10-17	2019-12-31	Macrophage Pharma Limited	N-[2-{4-[6-amino-5-(2,4-difluorobenzoilo)-2-oksopirydyn-1(2h)-ylo]-3,5-difluorofenylo}etylo)-L-alaninian tert-butylu lub jego sól, hydrat lub solwat
GB201713975D0 (en)	2017-08-31	2017-10-18	Macrophage Pharma Ltd	Medical use

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU650953B2 (en)	1991-03-21	1994-07-07	Novartis Ag	Inhaler
ATE375980T1 (de)	2002-02-12	2007-11-15	Smithkline Beecham Corp	Nicotinamide und deren verwendung als p38 inhibitoren
EP1487794A1 (en)	2002-03-14	2004-12-22	Bayer Aktiengesellschaft	Monocyclic aroylpyridinones as antiinflammatory agents
AU2006243000B2 (en)	2005-05-05	2011-05-26	Macrophage Pharma Limited	Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase
GB0509223D0 (en)	2005-05-05	2005-06-15	Chroma Therapeutics Ltd	Enzyme inhibitors
GB0509227D0 (en)	2005-05-05	2005-06-15	Chroma Therapeutics Ltd	Intracellular enzyme inhibitors
GB0509225D0 (en)	2005-05-05	2005-06-15	Chroma Therapeutics Ltd	Inhibitors of enzymatic activity
GB0510204D0 (en)	2005-05-19	2005-06-22	Chroma Therapeutics Ltd	Enzyme inhibitors
GB0608821D0 (en)	2006-05-04	2006-06-14	Chroma Therapeutics Ltd	DHFR enzyme inhibitors
GB0608837D0 (en)	2006-05-04	2006-06-14	Chroma Therapeutics Ltd	Inhibitors of MAP kinase
GB0608823D0 (en)	2006-05-04	2006-06-14	Chroma Therapeutics Ltd	Inhibitors of P13 kinase
EP2013175B9 (en) *	2006-05-04	2020-11-11	Macrophage Pharma Limited	p38 MAP KINASE INHIBITORS
GB0608855D0 (en) *	2006-05-04	2006-06-14	Chroma Therapeutics Ltd	Inhibitors of MAP kinase enzymes
GB0619753D0 (en)	2006-10-06	2006-11-15	Chroma Therapeutics Ltd	Enzyme inhibitors
EA200900593A1 (ru)	2006-10-25	2010-06-30	Хрома Терапьютикс Лтд.	Производные птеридина как ингибиторы polo-подобной киназы, применяющиеся при лечении рака
GB0621203D0 (en)	2006-10-25	2006-12-06	Chroma Therapeutics Ltd	PLK inhibitors
WO2008053131A1 (en)	2006-10-30	2008-05-08	Chroma Therapeutics Ltd.	Hydroxamates as inhibitors of histone deacetylase
JP2010508337A (ja)	2006-11-01	2010-03-18	クロマセラピューティクスリミテッド	Ｉｋｋ−ベータセリン−スレオニンプロテインキナーゼの阻害剤
WO2008053182A1 (en)	2006-11-01	2008-05-08	Chroma Therapeutics Ltd.	IKK-β SERINE-THREONINE PROTEIN KINASE INHIBITORS
US20100267774A1 (en)	2007-11-07	2010-10-21	Chroma Therapeutics Ltd.	P38 map kinase inhibitors
JP5555186B2 (ja) *	2008-02-29	2014-07-23	クロマセラピューティクスリミテッド	ｐ３８ＭＡＰキナーゼ阻害剤
GB0803747D0 (en)	2008-02-29	2008-04-09	Martin	Enzyme and receptor modulation
EP2297128B1 (en)	2008-04-23	2012-08-15	Chroma Therapeutics Ltd.	Inhibitors of ikk- serine-threonine protein kinase
GB0807451D0 (en)	2008-04-24	2008-05-28	Chroma Therapeutics Ltd	Inhibitors of PLK
MX2010011643A (es)	2008-04-26	2010-11-30	Chroma Therapeutics Ltd	Tiofencarboxamidas sustituidas como inhibidores de la proteina cinasa ikk-beta serina, treonina.
GB0903480D0 (en)	2009-02-27	2009-04-08	Chroma Therapeutics Ltd	Enzyme Inhibitors
GB0907120D0 (en)	2009-04-24	2009-06-03	Chroma Therapeutics Ltd	Inhibitors of IKK-ß serine-threonine protein kinase
GB201009853D0 (en)	2010-06-11	2010-07-21	Chroma Therapeutics Ltd	HSP90 inhibitors
GB201021467D0 (en)	2010-12-17	2011-02-02	Chroma Therapeutics Ltd	Imaging agents
GB201211310D0 (en)	2012-06-26	2012-08-08	Chroma Therapeutics Ltd	CSF-1R kinase inhibitors
PL3222616T3 (pl) *	2012-10-17	2019-12-31	Macrophage Pharma Limited	N-[2-{4-[6-amino-5-(2,4-difluorobenzoilo)-2-oksopirydyn-1(2h)-ylo]-3,5-difluorofenylo}etylo)-L-alaninian tert-butylu lub jego sól, hydrat lub solwat

2013
- 2013-10-15 PL PL17168533T patent/PL3222616T3/pl unknown
- 2013-10-15 RS RSP20191330 patent/RS59458B1/sr unknown
- 2013-10-15 JP JP2015537346A patent/JP6260975B2/ja not_active Expired - Fee Related
- 2013-10-15 MX MX2015004368A patent/MX364782B/es active IP Right Grant
- 2013-10-15 CN CN201610944341.3A patent/CN106496106B/zh not_active Expired - Fee Related
- 2013-10-15 CN CN201380054069.6A patent/CN104781235B/zh not_active Expired - Fee Related
- 2013-10-15 SM SM20170399T patent/SMT201700399T1/it unknown
- 2013-10-15 ES ES17168533T patent/ES2743768T3/es active Active
- 2013-10-15 CA CA2888928A patent/CA2888928C/en not_active Expired - Fee Related
- 2013-10-15 BR BR112015008167-3A patent/BR112015008167B1/pt not_active IP Right Cessation
- 2013-10-15 PT PT137833638T patent/PT2909175T/pt unknown
- 2013-10-15 SI SI201330714T patent/SI2909175T1/sl unknown
- 2013-10-15 RS RS20170646A patent/RS56184B1/sr unknown
- 2013-10-15 SM SM20190524T patent/SMT201900524T1/it unknown
- 2013-10-15 PL PL13783363T patent/PL2909175T3/pl unknown
- 2013-10-15 KR KR1020157012809A patent/KR102164536B1/ko not_active Expired - Fee Related
- 2013-10-15 EP EP17168533.2A patent/EP3222616B1/en active Active
- 2013-10-15 WO PCT/GB2013/052689 patent/WO2014060742A1/en not_active Ceased
- 2013-10-15 US US14/436,404 patent/US9388136B2/en not_active Expired - Fee Related
- 2013-10-15 PT PT17168533T patent/PT3222616T/pt unknown
- 2013-10-15 LT LTEP17168533.2T patent/LT3222616T/lt unknown
- 2013-10-15 SG SG10201708166SA patent/SG10201708166SA/en unknown
- 2013-10-15 IN IN2721DEN2015 patent/IN2015DN02721A/en unknown
- 2013-10-15 SI SI201331557T patent/SI3222616T1/sl unknown
- 2013-10-15 SG SG11201502515VA patent/SG11201502515VA/en unknown
- 2013-10-15 DK DK13783363.8T patent/DK2909175T3/en active
- 2013-10-15 HU HUE17168533A patent/HUE046132T2/hu unknown
- 2013-10-15 RU RU2015115213A patent/RU2676329C2/ru active
- 2013-10-15 EP EP13783363.8A patent/EP2909175B1/en active Active
- 2013-10-15 AU AU2013333636A patent/AU2013333636B2/en not_active Ceased
- 2013-10-15 HU HUE13783363A patent/HUE035525T2/en unknown
- 2013-10-15 ES ES13783363.8T patent/ES2635240T3/es active Active
- 2013-10-15 HR HRP20171320TT patent/HRP20171320T1/hr unknown
- 2013-10-15 DK DK17168533.2T patent/DK3222616T3/da active
- 2013-10-15 NZ NZ706717A patent/NZ706717A/en not_active IP Right Cessation
2015
- 2015-03-20 ZA ZA2015/01958A patent/ZA201501958B/en unknown
- 2015-03-22 IL IL237863A patent/IL237863B/en active IP Right Grant
2016
- 2016-06-15 US US15/183,612 patent/US9896417B2/en not_active Expired - Fee Related
2017
- 2017-07-17 CY CY20171100756T patent/CY1119080T1/el unknown
- 2017-10-11 JP JP2017197466A patent/JP6464244B2/ja not_active Expired - Fee Related
- 2017-12-25 IL IL256560A patent/IL256560B/en active IP Right Grant
2018
- 2018-01-03 US US15/861,586 patent/US10370332B2/en not_active Expired - Fee Related
2019
- 2019-09-23 CY CY20191101002T patent/CY1122194T1/el unknown
- 2019-10-15 HR HRP20191874TT patent/HRP20191874T1/hr unknown

Also Published As

Publication number	Publication date
HRP20191874T1 (hr)	2020-01-10
SG10201708166SA (en)	2017-11-29
AU2013333636A1 (en)	2015-04-09
US20180127371A1 (en)	2018-05-10
HUE046132T2 (hu)	2020-02-28
RS59458B1 (sr)	2019-11-29
WO2014060742A1 (en)	2014-04-24
JP2015534974A (ja)	2015-12-07
DK2909175T3 (en)	2017-08-14
KR20150067376A (ko)	2015-06-17
NZ706717A (en)	2018-02-23
US10370332B2 (en)	2019-08-06
US9896417B2 (en)	2018-02-20
SMT201700399T1 (it)	2017-09-07
CY1122194T1 (el)	2020-11-25
MX364782B (es)	2019-05-07
EP2909175B1 (en)	2017-06-07
CN104781235B (zh)	2016-12-21
EP3222616A1 (en)	2017-09-27
LT3222616T (lt)	2019-09-10
PL2909175T3 (pl)	2017-10-31
BR112015008167B1 (pt)	2020-11-17
ES2743768T3 (es)	2020-02-20
SMT201900524T1 (it)	2019-11-13
SI2909175T1 (sl)	2017-08-31
CA2888928C (en)	2020-05-26
RU2015115213A (ru)	2016-12-10
ES2635240T3 (es)	2017-10-03
CN106496106B (zh)	2019-05-10
EP2909175A1 (en)	2015-08-26
SI3222616T1 (sl)	2019-10-30
DK3222616T3 (da)	2019-08-19
PL3222616T3 (pl)	2019-12-31
MX2015004368A (es)	2015-06-10
IN2015DN02721A (sr)	2015-09-04
IL256560B (en)	2019-07-31
IL256560A (en)	2018-02-28
HK1211028A1 (en)	2016-05-13
JP2018048160A (ja)	2018-03-29
US9388136B2 (en)	2016-07-12
JP6464244B2 (ja)	2019-02-06
IL237863B (en)	2018-06-28
HUE035525T2 (en)	2018-05-28
RS56184B1 (sr)	2017-11-30
CY1119080T1 (el)	2018-01-10
BR112015008167A2 (pt)	2017-07-04
JP6260975B2 (ja)	2018-01-17
SG11201502515VA (en)	2015-05-28
RU2676329C2 (ru)	2018-12-28
PT3222616T (pt)	2019-09-26
US20160297760A1 (en)	2016-10-13
KR102164536B1 (ko)	2020-10-12
AU2013333636B2 (en)	2017-11-23
US20150246883A1 (en)	2015-09-03
PT2909175T (pt)	2017-09-13
EP3222616B1 (en)	2019-07-17
HRP20171320T1 (hr)	2017-10-20
CA2888928A1 (en)	2014-04-24
CN104781235A (zh)	2015-07-15
CN106496106A (zh)	2017-03-15

Publication	Publication Date	Title
NO2023038I1 (no)	2023-10-13	Ivosidenib or a pharmaceutically acceptable salt, tautomer, isotopologue or hydrate thereof
IL239563B (en)	2018-02-28	Derivatives of -n(converted)-5-fluoro-4-imino-3-methyl-2-oxo-4,3-dihydropyrimidine-1 (h2)-carboxamides
NO2019013I1 (no)	2019-03-28	vaborbactam, and/or a salt and/or hydrate thereof
PL2945403T3 (pl)	2017-07-31	Profilowanie użytkownika z użyciem danych lokalizacji z analizowanej ścieżki użytkownika
PT2657233E (pt)	2014-10-24	Composto de alcinil-benzeno substituído nas posições 3 e 5 e um seu sal
SG2014010466A (en)	2014-09-26	Method to control the access of personal data of a user
IL239561B (en)	2018-01-31	Derivatives of n-(converted)-5-fluoro-4-imino-3-methyl-2-oxo-4,3-dihydropyrimidine-1(2h)-carboxylate
GB201610846D0 (en)	2016-08-03	Methods of authenticating a user for data exchange
IL235681A0 (en)	2015-02-01	5- amino [1, 4] thiazines as 1 bace inhibitors
IL267303B (en)	2021-01-31	Method for the production of -7-(3,4-dichloro-2-fluorophenylamino)-4)-4)-1 methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one
ZA201604932B (en)	2019-04-24	N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase
IL256560B (en)	2019-07-31	tert-butyl n-[2-{4-[6-amino-5-(4,2-difluorobenzoyl)-2-oxopyridine-1(2h)-yl]-5,3-difluorophenyl}ethyl]-l-alanine or a salt, hydrate or solvate thereof
SMT201700528T1 (it)	2018-01-11	2-alchil-1-osso-n-fenil-3-eteroaril-1,2,3,4-tetraidroisochinolin-4-carbossammidi sostituite per le terapie antimalariche
ZA201503924B (en)	2020-11-25	A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc)
IL238829B (en)	2018-02-28	Process for the preparation of 4-(cyclopropylmethoxy-3,5)-n-(dichloro-1-oxido-4-pyridyl)-5-methoxypyridine-2-carboxamide
GB2508849B (en)	2014-11-05	Backing-up user data
EP2745199A4 (en)	2015-04-01	TRACKING DATA BLOCK OPERATIONS
PL390799A1 (pl)	2011-09-26	Komputer, zwłaszcza dla stanowiska typu POS
TWM433267U (en)	2012-07-11	Tool set with pivotally changed head
AU336302S (en)	2011-05-04	'SATIN' Ruche sleeve tunic
GB201106039D0 (en)	2011-05-25	Personal computer locks automatically,as the user moves away